Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly

Pituitary

Volumn 15, Issue 1, 2012, Pages 97-100

  Morin, Emilie ^a   Berthelet, France ^a   Weisnagel, John ^b   Bidlingmaier, Martin ^c   Serri, Omar ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acromegaly; Pegvisomant; Somatostatin analogues; Temozolomide

Indexed keywords

GROWTH HORMONE; KI 67 ANTIGEN; OCTREOTIDE; PEGVISOMANT; PROTEIN P53; SOMATOMEDIN C; TEMOZOLOMIDE;

ACROMEGALY; ADULT; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CASE REPORT; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EYE EXAMINATION; GALLSTONE; HEADACHE; HEMIANOPIA; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOPATHOLOGY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REOPERATION; TRANSSPHENOIDAL HYPOPHYSECTOMY; TUMOR VOLUME;

ACROMEGALY; ADULT; DACARBAZINE; HUMAN GROWTH HORMONE; HUMANS; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959922097     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-010-0232-9     Document Type: Article

References (17)

1. Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L et al (2001) Long term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759 (Pubitemid 33152999)
2. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, Van der Lely AJ et al (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644-1646 (Pubitemid 40693415)
3. Hagen C, Schroeder HD, Hansen S, Andersen M (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161:631-637
4. Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC et al (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphology findings. Hum Pathol 38:185-189 (Pubitemid 44880216)
5. Syro LV et al (2009) Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones 8(4):303-306
6. Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD (2009) Use of Temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64:773-774
7. Neff LM et al (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10(1):81-86 (Pubitemid 46562811)
8. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE et al (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65:552-553 (Pubitemid 44414285)
9. Obari et al (2008) Clinicopathological features of growth hormone- producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82-91
10. Bhayana et al (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90:6290-6295 (Pubitemid 41606558)
11. Barlier et al (1999) Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 84:2759-2765 (Pubitemid 30642008)
12. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189-3202
13. Maiza JC, Caron P (2009) Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options. Ann Endocrinol (Paris) 70(Suppl 1):S12-S19 (French)
14. Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV et al (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115:261-262
15. Esteller M et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New Engl J Med 343:1350-1354
16. Bonert VS, Kennedy L, Petersenn S et al (2008) Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 93:3515-3518
17. Moore DJ, Adi Y, Connock MJ, Bayliss S (2009) Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord 9:20. doi:10.1186/1472-6823-9- 20